2024-01-17 10:33:11
Via SNS, “Submitted to the Suwon District Court an application for a provisional injunction to prohibit the issuance of new shares.”
Lim Jong-yoon and Lim Jong-hoon shareholding ratio of 19.22% vs. Song Young-sook and Lim Ju-hyun 19.85%.
[데일리팜=김진구 기자] Lim Jong-yoon and Lim Jong-hoon, CEOs of Hanmi Pharmaceutical, filed an application for a provisional injunction with the Suwon District Court to block the integration between Hanmi Group and OCI Group. The analysis is that the conflict over management rights in the Hanmi Group has become serious due to the confrontation between brothers and mother and daughter.
Lim Jong-yoon, CEO of Hanmi Pharmaceutical, announced on the 17th through Corey Group’s Twitter (X), “Lim Jong-yoon and Lim Jong-hoon jointly submitted an application for a provisional injunction to prohibit the issuance of new shares to the Suwon District Court.” Corey Group’s CEO Lim Jong-yoon is the largest shareholder.
The integration contract between Hanmi Group and OCI Group was concluded through in-kind investment and new share issuance. OCI Holdings will spend 240 billion won to secure 6,434,315 new shares of Hanmi Science by participating in Hanmi Science’s third-party allocation capital increase. President Lim Jong-yoon’s side filed an application for a provisional injunction to block the issuance of new shares.
In particular, attention is focused on the fact that President Lim Jong-hoon, the younger brother of President Lim Jong-yoon, joined in this legal action. With the addition of President Lim Jong-hoon, the shareholding ratios of Lim Jong-yoon and Lim Jong-hoon and Song Young-sook and Lim Joo-hyeon became similar.
Presidents Jong-yoon Lim and Jong-hoon Lim own 12.12% and 7.20% of shares in Hanmi Science as of the end of the third quarter of last year. The combined share of the two people amounts to 19.22%.
Hanmi Science Chairman Song Young-sook and Hanmi Pharmaceutical President Lim Joo-hyun, who led the integration with OCI Group, have a 19.85% stake (Song Young-sook 12.56%, Lim Joo-hyun 7.29%).
As the basis for applying for a provisional injunction, President Lim Jong-yoon is arguing that a paid-in capital increase through third-party allocation is illegal in a management rights dispute.
If the court accepts the request for a preliminary injunction, the integration work between Hanmi Group and OCI Group will be put on hold. On the other hand, if the request for a preliminary injunction is dismissed, integration is expected to accelerate.
President Lim Jong-yoon hinted at a management rights dispute on the 13th. At the time, he said through Corey Group’s Twitter ( “I will express my position,” he said.
Reporter Kim Jin-gu (kjg@dailypharm.com)
1705490993
#데일리팜 #KoreaUS #management #dispute #intensifies.. #Lim #Jongyoon #Lim #Jonghoon #legal #action
